Abstract |
Between 1973 and 1982, 110 patients with advanced Hodgkin's disease who had had disease progression while receiving MOPP ( mechlorethamine, vincristine, procarbazine, and prednisone) chemotherapy or a relapse after a MOPP-induced complete remission were treated with either ABVD ( doxorubicin, bleomycin, vinblastine, and dacarbazine) (58 patients) or B-CAVe ( bleomycin, lomustine, doxorubicin, and vinblastine) (52 patients) chemotherapy in concurrent nonrandomized trials. Responses were seen in 39 of 55 (71%) evaluable ABVD-treated patients--21 (38%) complete and 18 partial responses--and in 34 of 48 (71%) evaluable B-CAVe-treated patients--21 (44%) complete and 13 partial responses. The median duration of the ABVD-induced complete remissions is greater than 25 months compared with 24.3 months for B-CAVe-induced remissions. The 5-year actuarial freedom from progression is 8.5% for evaluable ABVD-treated patients and 25% for B-CAVe-treated patients (p = 0.10). Toxicity in the two treatment groups was similar, with only significant thrombocytopenia (platelet count, less than 50 000/mm3) being more common with B-CAVe. Although most patients with Hodgkin's disease refractory to MOPP treatment will respond to either ABVD or B-CAVe chemotherapy, subsequent long-term disease-free survival is unusual. The need for improved treatment programs for this patient group is evident.
|
Authors | W G Harker, P Kushlan, S A Rosenberg |
Journal | Annals of internal medicine
(Ann Intern Med)
Vol. 101
Issue 4
Pg. 440-6
(Oct 1984)
ISSN: 0003-4819 [Print] United States |
PMID | 6206757
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Bleomycin
- Procarbazine
- Mechlorethamine
- Vincristine
- Vinblastine
- Lomustine
- Dacarbazine
- Doxorubicin
- Prednisone
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Bleomycin
(administration & dosage, adverse effects)
- Combined Modality Therapy
- Dacarbazine
(administration & dosage, adverse effects)
- Doxorubicin
(administration & dosage, adverse effects)
- Drug Resistance
- Female
- Heart Diseases
(chemically induced)
- Hodgkin Disease
(drug therapy)
- Humans
- Lomustine
(administration & dosage, adverse effects)
- Lung Diseases
(chemically induced)
- Male
- Mechlorethamine
(administration & dosage)
- Middle Aged
- Neoplasm Recurrence, Local
- Prednisone
(administration & dosage)
- Procarbazine
(administration & dosage)
- Vinblastine
(administration & dosage, adverse effects)
- Vincristine
(administration & dosage)
|